| Blanc, François-Xavier |
| Recruiting | 4 | 220 | Europe | Benralizumab Prefilled Syringe, Transcriptomic | Nantes University Hospital, AstraZeneca, Ministère de la Santé - France | Asthma; Eosinophilic, Severe Asthma | 10/26 | 11/26 | | |
| Active, not recruiting | 3 | 1667 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 10/25 | 10/25 | | |
|
ANTEIPA, NCT06368804: Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis |
|
|
| Recruiting | 2 | 196 | Europe | Antibiotic monotherapy treatment and follow-up, Antibiotic bitherapy treatment and follow-up | Centre Hospitalier Intercommunal Creteil, Assistance Publique - Hôpitaux de Paris | Bronchiectasis | 03/25 | 09/28 | | |
NaRacAS, NCT03325088: Assessing the Expression and the Activity of Rac1 Protein in the Airway Smooth Muscle of Asthmatic Patient |
|
|
| Completed | N/A | 24 | Europe | Bronchial endoscopy, Bronchial biopsies, Bronchial alveolar enema | Nantes University Hospital, L'institut du thorax - INSERM UMR 1087 / CNRS UMR6291 - IRS-Université de Nantes, IRSR-PL : Institut de Recherche en Santé Respiratoire des Pays de La Loire | Asthma | 11/23 | 11/23 | | |
EXAP, NCT05525169: Study of the Impact of Exposure to Outdoor and Indoor Pollutants in Patients With Asthma |
|
|
| Recruiting | N/A | 30 | Europe | | Nantes University Hospital | Asthma | 09/25 | 09/25 | | |
| Rialland, Fanny |
TAK-620-2004, NCT05319353 / 2021-004279-15: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT) |
|
|
| Active, not recruiting | 3 | 80 | Europe, Japan, US, RoW | Maribavir, TAK-620 | Takeda, Takeda Development Center Americas, Inc. | Cytomegalovirus (CMV) | 01/27 | 01/27 | | |
| Recruiting | 2/3 | 1800 | Europe, Canada, RoW | VP16, Etoposide, TBI, Thiotepa, Thio, Treosulfan, Treo, Fludarabine, Flu, Busulfan, Bu, ATG Thymoglobulin, ATG Thymo, Cyclophosphamide, Cy, Grafalon, Anti-human T-lymphocyte immunoglobulin | St. Anna Kinderkrebsforschung, ALL SCTped Forum, European Society for Blood and Marrow Transplantation, ALL-BFM Study Group, Assistance Publique - Hôpitaux de Paris, Dutch Childhood Oncology Group, Swiss Pediatric Oncology Group, Australian & New Zealand Children's Haematology/Oncology Group | Acute Lymphoblastic Leukaemia | 06/25 | 04/30 | | |
HAPLO-EMPTY, NCT05126849: Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression |
|
|
| Recruiting | 2 | 31 | Europe | Allogenic transplantation | Assistance Publique - Hôpitaux de Paris | Refractory Idiopathic Aplastic Anemia, Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation | 01/27 | 01/27 | | |
CAPTiRALL, NCT05310591 / 2021-003035-28: Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence |
|
|
| Recruiting | 1/2 | 26 | Europe | Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) ), Nivolumab starting at day -1 | Assistance Publique - Hôpitaux de Paris, DGOS | B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | 03/27 | 03/27 | | |
HEM-iSMART D, NCT05658640: HEM ISMART-D: Trametinib + Dexamethasone + Chemotherapy in Children with Relapsed or Refractory Hematological Malignancies |
|
|
| Recruiting | 1/2 | 26 | Europe, RoW | Trametinib, Dexamethasone, Cyclophosphamide, Cytarabine, Intrathecal chemotherapy | Princess Maxima Center for Pediatric Oncology, Innovative Therapies For Children with Cancer Consortium, IBFM, Fight Kids Cancer | Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory | 04/29 | 04/29 | | |
ALARM3, NCT05772559: Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies |
|
|
| Recruiting | N/A | 500 | Europe | Collection of blood sample of bone marrow (cohort 1), Collection of blood sample of bone marrow (cohort 2 and 3) | Assistance Publique - Hôpitaux de Paris | Acute Myeloid Leukemia, Genetic Predisposition to Disease | 05/33 | 05/33 | | |
| Cariou, Bertrand |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
| Completed | N/A | 51 | Europe | Patient group, Remission control group, Bilateral surrenalectomy control group | University Hospital, Bordeaux | Cushing Disease | 06/22 | 06/22 | | |
STEATO-POMPE, NCT04270656: Liver and Metabolic Effects of Insulin Pump Therapy in Diabetics Type 2 with Non-alcoholic Hepatic Steatosis |
|
|
| Completed | N/A | 46 | Europe | Insulin pump therapy, Multi-injection treatment ( MDI ). | Nantes University Hospital, University Hospital, Angers | Type 2 Diabetes (T2D) | 09/24 | 09/24 | | |
| Active, not recruiting | N/A | 366 | Europe | Pre-diabetes screening | Nantes University Hospital | Pre-diabetes | 06/23 | 06/23 | | |
| Recruiting | N/A | 1000 | Europe | Non-invasive blood-based and imaging-based tests for the screening of NAFLD-related advanced fibrosis. | Hospices Civils de Lyon | Non-Alcoholic Fatty Liver Disease | 10/23 | 10/23 | | |
| Recruiting | N/A | 806 | Europe | Blood tests | Nantes University Hospital | Diabetes Mellitus, Type 2, NAFLD, NASH | 03/25 | 03/25 | | |
| Asehnoune, karim |
| Not yet recruiting | N/A | 5000 | Europe | questionnaire filling | Centre Hospitalier Universitaire de NÄ«mes | Critical Illness, Covid19, Stress Disorders, Post-Traumatic | 09/22 | 09/22 | | |
GOAL, NCT03461900: Guided Fluid-balance Optimization With Mini-fluid chALlenge During Septic Shock |
|
|
| Completed | N/A | 535 | Europe | Minifluid challenge, Usual practice | University Hospital, Brest | Septic Shock | 08/23 | 01/24 | | |
| Completed | N/A | 94 | Europe | Baclofen, Placebo | Nantes University Hospital | Alcoholism, Post Traumatic Stress Disorder | 02/24 | 02/24 | | |
| Recruiting | N/A | 770 | Europe | High flow Oxygenation, Standard oxygen | University Hospital, Brest | Chest Trauma, High Flow Oxygenation | 02/26 | 02/26 | | |
| Recruiting | N/A | 660 | Europe | Extubation readiness clinical score, Standard of care | University Hospital, Clermont-Ferrand, AZUREA Network (www.azurea.org), ANARLF Network, Direction Générale de l'Offre de Soin (DGOS) | Mechanical Ventilator Weaning, Acute Brain Injury, Altered Level of Consciousness, Mechanical Ventilation, Airway Control | 02/27 | 10/27 | | |
ATLANREA, NCT02714387: Non Traumatic Neuro-Vascular Diseases Critical Complications : a Prospective Cohort Study |
|
|
| Recruiting | N/A | 5000 | Europe | Collection of medical data | Nantes University Hospital | Non Traumatic Acute Brain Injury | 01/50 | 01/50 | | |
NCT02426255: Post Traumatic Critical Complications: a Prospective Cohort Study (ATLANREA) |
|
|
| Recruiting | N/A | 5000 | Europe | Collection of medical data from ICU patients | Nantes University Hospital | Severe Trauma (With or Without Traumatic Brain Injury) | 01/50 | 01/50 | | |
| MILPIED, Noel |
ICTUS, NCT04003220: Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker |
|
|
| Recruiting | N/A | 80 | Europe | blood sample, Bone marrow sample | University Hospital, Bordeaux, Institut National de la Santé Et de la Recherche Médicale, France | Thrombocytopenia, Purpura, Thrombocytopenic, Myelodysplastic Syndromes | 09/23 | 09/23 | | |
| MAGNAN, Antoine |
| Recruiting | 4 | 220 | Europe | Benralizumab Prefilled Syringe, Transcriptomic | Nantes University Hospital, AstraZeneca, Ministère de la Santé - France | Asthma; Eosinophilic, Severe Asthma | 10/26 | 11/26 | | |
| Active, not recruiting | 3 | 1667 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 10/25 | 10/25 | | |
|
| BARBAROT, Sébastien |
| Not yet recruiting | N/A | 100 | Europe | | Nantes University Hospital, LEO Pharma | Atopic Dermatitis | 07/25 | 03/26 | | |
| CHAILLOUS, Lucy |
| Completed | N/A | 90 | Europe | Use of the DBLG1 system | Diabeloop, Icadom | Diabetes Mellitus, Type 1 | 02/24 | 04/24 | | |
| Recruiting | N/A | 160 | Europe | Insulin Management System in Manual mode of operation, Insulin Management System in Automatic mode of operation | Medtrum France, Axonal-Biostatem | Type 1 Diabetes | 11/25 | 12/25 | | |
| Recruiting | N/A | 348 | Europe | DBLG1 System | Diabeloop | Type1diabetes | 07/25 | 01/26 | | |
| ROQUILLY, Antoine |
HAP-DEX, NCT06269900: Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype |
|
|
| Recruiting | 3 | 450 | Europe | Dexamethasone, Placebo | Nantes University Hospital | Hospital Acquired Pneumonia | 03/26 | 08/26 | | |
| Not yet recruiting | 3 | 1218 | Europe | direct IV injection, combination of Ketamine and Propofol | Nantes University Hospital | Rapid Sequence Induction | 03/27 | 04/27 | | |
| Completed | 3 | 700 | Europe | Inhaled sedation with sevoflurane, intravenous sedation with propofol | University Hospital, Clermont-Ferrand | Acute Respiratory Distress Syndrome | 10/23 | 10/24 | | |
PLATINIUM, NCT06774235: Prevention of Secondary Infections by Interferon Gamma in ICU-acquired Sustained Immune-suppression |
|
|
| Not yet recruiting | 3 | 326 | Europe | Interferon Gamma 1-b, Placebo | University Hospital, Limoges | Sustained Immunosuppression | 09/28 | 09/28 | | |
TREAT-HAP, NCT05914584: "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype. |
|
|
| Not yet recruiting | 3 | 450 | Europe | Baricitinib 4 MG | Nantes University Hospital | Hospital-acquired Pneumonia | 08/25 | 12/25 | | |
RECOVER, NCT06370598: Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia |
|
|
| Not yet recruiting | 1/2 | 15 | Europe | TP-122A | Technophage, SA, VectorB2B | Pneumonia, Ventilator-Associated | 05/25 | 06/25 | | |
| Not yet recruiting | N/A | 5000 | Europe | questionnaire filling | Centre Hospitalier Universitaire de NÄ«mes | Critical Illness, Covid19, Stress Disorders, Post-Traumatic | 09/22 | 09/22 | | |
HOMI-LUNG-HAP, NCT06602934: Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia |
|
|
| Recruiting | N/A | 300 | Europe | Blood samples, Oropharyngeal swabs, Calcium score (CT scan), ECG, Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration, and 6-minute walk test | Nantes University Hospital | Hospital Acquired Pneumonia (HAP), Cardiovascular and Respiratory Disease | 01/29 | 05/29 | | |
| Recruiting | N/A | 75 | Europe | Voluntary | Nantes University Hospital | Healthy Patients | 07/27 | 07/27 | | |
| Recruiting | N/A | 62 | Europe | alveolar recruitment maneuvers group 1, alveolar recruitment maneuvers group 2 | University Hospital, Toulouse | Cerebral Injuries, Acute Respiratory Distress Syndrome (ARDS) | 12/25 | 12/25 | | |
NCT02426255: Post Traumatic Critical Complications: a Prospective Cohort Study (ATLANREA) |
|
|
| Recruiting | N/A | 5000 | Europe | Collection of medical data from ICU patients | Nantes University Hospital | Severe Trauma (With or Without Traumatic Brain Injury) | 01/50 | 01/50 | | |
| REIGNIER, Jean |
| Recruiting | 3 | 610 | Europe | Levosimendan 2.5 MG/ML Injectable Solution, Placebo | Central Hospital, Nancy, France | Cardiogenic Shock | 02/27 | 01/28 | | |
Corticop, NCT04163536: Comparison of Corticosteroids vs Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the ICU |
|
|
| Recruiting | 3 | 440 | Europe | Methylprednisolone, Placebos | Versailles Hospital | Chronic Obstructive Pulmonary Disease | 10/25 | 03/26 | | |
TestICUs, NCT05825092: Effects of Early Testosterone Gel Administration on Physical Performance in the Critically Ill |
|
|
| Recruiting | 2 | 600 | Europe | Androgel Topical Product, Androgel 1.62% Transdermal Gel, Placebo, Physical performance, Muscle strength, Muscular mass, Test: Functional status, Oxygen muscular consumption | University Hospital, Clermont-Ferrand | Critical Illness | 09/25 | 04/27 | | |
| Completed | N/A | 1346 | Europe, RoW | Family members of patients admitted to the ICU, Health care professionals, Patients | Nantes University Hospital, Assistance Publique - Hôpitaux de Paris, Assistance Publique Hopitaux De Marseille | Stress Disorders, Post-Traumatic, Family Members | 01/24 | 09/24 | | |
| Not yet recruiting | N/A | 754 | Europe | Strategy for continuing oral intake, Fasting strategy | University Hospital, Tours | Patient in Acute Respiratory Failure, Continuation of Oral Intake | 09/27 | 10/27 | | |
NUTRIREA-4, NCT06581939: Impact of an Early and Extended Rehabilitation Program Combining Individually Tailored Nutrition and Physical Activities on Patient Outcomes After Invasive Mechanical Ventilation and Vasopressor Therapy in the ICU |
|
|
| Recruiting | N/A | 830 | Europe | Rehabilitation group, Control group | Nantes University Hospital | Mechanical Ventilation | 06/27 | 12/27 | | |
XPRESSE, NCT04950270: Copeptin Kinetics in Critically Ill Patients With Posterior Reversible Encephalopathy Syndrome |
|
|
| Completed | N/A | 24 | Europe | Blood copeptin monitoring, phone interview | University Hospital, Tours | Posterior Reversible Encephalopathy Syndrome | 02/24 | 02/24 | | |
PROBIty, NCT05686577: How to Reduce Unnecessary Blood Cultures: Construction and Validation of a Predictive Score for Blood Culture Positivity in Intensive Care |
|
|
| Completed | N/A | 2411 | Europe | no intervention | University Hospital, Tours | Infection, Bacterial, Infection, Fungal, Bacteremia | 09/23 | 10/23 | | |
| LAPLAUD, David |
| Recruiting | 3 | 126 | Europe | Azathioprine, Placebo | Hospices Civils de Lyon | Central Nervous System Inflammation, MOG-IgG Associated Disease | 12/26 | 12/29 | | |
| Active, not recruiting | 3 | 72 | Europe | Ocrelizumab | Centre Hospitalier Universitaire de Nice | Multiple Sclerosis | 02/26 | 02/29 | | |
STOP-I-SEP, NCT03653273: Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years |
|
|
| Recruiting | 3 | 250 | Europe | DMT withdrawal, DMT continuation | Rennes University Hospital | Multiple Sclerosis | 07/26 | 01/28 | | |
TRIO, NCT05758831: RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. |
|
|
| Recruiting | 3 | 386 | Europe | Perfusion of treatment Rituximab, Perfusion of treatment Ocrelizumab | Rennes University Hospital | Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis | 03/30 | 05/30 | | |
NCT02912897: Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy With Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients With a First Clinical Episode Highly Suggestive of Multiple Sclerosis |
|
|
| Recruiting | 1 | 7 | Europe | Cellular therapy with EBV specific autologous CTL infusion | Nantes University Hospital | Multiple Sclerosis | 11/26 | 11/26 | | |
OUTCOMS, NCT04873492: From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis |
|
|
| Recruiting | N/A | 130 | Europe | Biological sample collection | Nantes University Hospital | Multiple Sclerosis | 07/23 | 07/25 | | |
Tys at Home, NCT04777539: Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis |
|
|
| Active, not recruiting | N/A | 279 | Europe | At-home natalizumab treated MS patient | Nantes University Hospital, Rennes University Hospital | Multiple Sclerosis (MS) | 11/24 | 05/25 | | |
| Recruiting | N/A | 1000 | Europe, RoW | No intervention | Hospices Civils de Lyon | Sclerosis, Multiple, Neuromyelitis Optica Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders, Pregnancy Abnormal | 08/36 | 08/36 | | |
| ROUAUD, Tiphaine |
| Active, not recruiting | 3 | 134 | Europe | Apomorphine, Apokinon, Best Medical Treatment | Rennes University Hospital | Parkinson's Disease | 12/23 | 01/25 | | |
PIMPARK, NCT03947216: Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. |
|
|
| Completed | 2 | 117 | Europe | Active drug: pimavanserin 17mg (2 strength tablets), Placebo: 2 tablets containing same excipients except active compound, Assessment of severity of ICD (impulse control disorders), Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors, Assessment of quality of life, Assessment of depression, Assessment of cognition, Assessment of severity of Parkinson Disease, Blood analysis, Cardiac monitoring | University Hospital, Strasbourg, France, NS-PARK, EUCLID Clinical Trial Platform, F-CRIN, ACADIA Pharmaceuticals Inc. | Parkinson Disease | 04/24 | 06/24 | | |
NCT03940872: Primary Parkinsonian Pain Diagnostic Questionnaire: Development and Validation of This Questionnaire |
|
|
| Completed | N/A | 227 | Europe | Self-questionnaire 3PDQ | University Hospital, Toulouse | Parkinson Disease | 12/22 | 12/22 | | |
RETRO-PIMPARK, NCT06754553: Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. |
|
|
| Not yet recruiting | N/A | 100 | Europe | Assessment of severity of ICD (impulse control disorders), Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors, Assessment of quality of life, Assessment of depression, Assessment of cognition, Assessment of severity of Parkinson Disease, Cardiac monitoring | University Hospital, Strasbourg, France, NS-PARK Network, EUCLID Clinical Trial Platform, F-CRIN | Parkinson Disease | 02/26 | 02/26 | | |
| BACCHETTA, Justine |
ITS-PILOT, NCT03582800: Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study |
|
|
| Recruiting | 2 | 40 | Europe | STS | University Hospital, Limoges | Systemic Sclerosis, Dermatomyositis, iPPSD2 | 06/25 | 06/25 | | |
| Not yet recruiting | N/A | 25 | Europe | Serum PTH concentrations results | Hospices Civils de Lyon | Hyperparathyroidism, Secondary, Hyperparathyroidism, Primary | 01/21 | 12/23 | | |
DAILY-LUMA, NCT06225882: Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France. |
|
|
| Recruiting | N/A | 100 | Europe | Oxaluria evolution. | Hospices Civils de Lyon | Patients With PH1 Treated With Lumasiran in France | 01/24 | 12/26 | | |
FLAM-XLH, NCT06248632: Effect of Burosumab on the Inflammatory Profile of Patients With X-linked Hypophosphatemic Rickets |
|
|
| Not yet recruiting | N/A | 20 | NA | Expression of inflammatory markers (Il6, Il8, Il1β, CXCL1, CCL2, CXCR3, Il1R, Il6R) | Hospices Civils de Lyon | X-Linked Hypophosphatemic Rickets | 04/25 | 04/25 | | |
| Recruiting | N/A | 20 | Europe | osteoblast biology study | Hospices Civils de Lyon | Craniosynostoses | 04/26 | 04/26 | | |
| Recruiting | N/A | 50 | Europe, RoW | Blood sampling | Hospices Civils de Lyon | Nephropathic Cystinosis | 10/24 | 10/24 | | |
| Recruiting | N/A | 3000 | Europe | No intervention | European Georges Pompidou Hospital, Oscar - Filière Santé Maladies Rares | Hypoparathyroidism | 09/30 | 09/31 | | |
| Recruiting | N/A | 186 | Europe | | University Hospital, Strasbourg, France | Primary Hyperoxaluria | 01/23 | 01/23 | | |
| GOFF, Benoit LE |
| Recruiting | N/A | 300 | Europe | | University Hospital, Brest | Inflammatory Rheumatism, Polymyalgia Rheumatica, Giant Cell Arteritis, Idiopathic Inflammatory Myopathies, ANCA Associated Vasculitis, Systemic Autoimmune Disease | 03/24 | 03/24 | | |
MAJIK, NCT04602091: Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism |
|
|
| Recruiting | N/A | 2300 | Europe | no intervention | Societe Francaise de Rhumatologie, Bordeaux PharmacoEpi | Rheumatoid Arthritis, Inflammatory Rheumatism, Psoriatic Arthritis, Spondyloarthritis | 06/26 | 06/30 | | |
| Not yet recruiting | N/A | 1000 | Europe | arthroplasty, Medical and non-medical treatments | University Hospital, Brest | Osteoarthritis, Knee | 07/30 | 07/30 | | |
| Bulteau, Samuel |
| Active, not recruiting | N/A | 119 | Europe | Systematic maintenance rTMS, rTMS course in case of relapse, sham rTMS | Nantes University Hospital | Treatment-resistant Depression | 12/22 | 12/23 | | |
| Recruiting | N/A | 64 | Europe | Electroconvulsive therapy | Centre Hospitalier du Rouvray, University Hospital, Rouen, University Hospital, Bordeaux, Nantes University Hospital, University Hospital, Toulouse, University Hospital, Caen, Centre Hospitalier Henri Laborit, Centre Hospitalier St Anne, Centre Hospitalier de Cadillac, Hôpital Louis Mourier, University Hospital, Montpellier, University Hospital, Clermont-Ferrand, Centre hospitalier de Ville-Evrard, France | Schizophrenia, Electroconvulsive Therapy | 10/23 | 10/23 | | |
| Recruiting | N/A | 150 | Europe | inflammatory, neuropsychological and neuroimaging assessment | Rennes University Hospital | Depression | 01/24 | 01/24 | | |
| LEVESQUE, Amélie |
CAPSACOX, NCT06023706: Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia. |
|
|
| Recruiting | 3 | 188 | Europe | Capsaicin 179 Mg Cutaneous Patch, qutenza, Capsaicin low concentration patch (capsaicin 0,04%, 3,2 mg/cm2) | Nantes University Hospital | Coccyx Disorder, Neuropathic Pain, Coccygodynia | 01/27 | 06/27 | | |
| VOURC'H, Mickael |
EPITUBE-HEART, NCT05335954: Therapeutic Study Evaluating the Efficacy of Noradrenaline in the Prevention of Hypotension Related to Intubation for Cardiac or Thoracic Surgery |
|
|
| Completed | 3 | 211 | Europe | noradrenaline | Nantes University Hospital | Cardiac Disorder, Hypotension | 12/23 | 12/23 | | |
HAP-DEX, NCT06269900: Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype |
|
|
| Recruiting | 3 | 450 | Europe | Dexamethasone, Placebo | Nantes University Hospital | Hospital Acquired Pneumonia | 03/26 | 08/26 | | |
NCT04389463: Patient Outcome of Cardiac Surgery During the COVID-19 Pandemic |
|
|
| Recruiting | N/A | 350 | Europe | No intervention | Nantes University Hospital | Patients Undergoing Cardiac or Thoracic Surgery | 05/22 | 06/22 | | |
ARTIST, NCT05126524: Loco-regional Anaesthesia in Video or Robot-assisted Thoracic Pulmonary Surgery |
|
|
| Completed | N/A | 456 | Europe | NO INTERVENTION | Société Française d'Anesthésie et de Réanimation | Pulmonary Surgical Procedures | 09/22 | 12/22 | | |
| Recruiting | N/A | 702 | Europe | No ventilation with face mask, Ventilation with face mask | Nantes University Hospital | Morbid Obesity, Ventilation Therapy; Complications | 09/25 | 09/25 | | |
| Fort, Marc Le |
GASPARD-SCI, NCT05403606: "Guarantee Assessment in Skin Prevention Adapted to Real Life With a Connected Device After a Spinal Cord Injury." |
|
|
| Not yet recruiting | N/A | 242 | NA | GASPARD® | Nantes University Hospital | Spinal Cord Injury | 06/25 | 06/25 | | |
| GUILLON, Benoit |
THEIA, NCT03197194: A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion |
|
|
| Completed | 3 | 70 | Europe | Alteplase, Actilyse, acetylsalicylic acid, Aspirin, Placebo Oral Tablet, Placebo aspirin, placebo IV, Placebo Actilyse | Nantes University Hospital | Central Retinal Artery Occlusion | 01/24 | 01/24 | | |
CLOSE-2, NCT05387954: PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years |
|
|
| Recruiting | 3 | 792 | Europe | Transcatheter PFO closure, •Each device for PFO closure must have the CE mark, •and be approved by the Interventional Cardiology Committee, Oral Anticoagulant, Direct-Acting, Antiplatelet therapy | Assistance Publique - Hôpitaux de Paris, Ministry of Health, France, W.L.Gore & Associates, Abbott, Occlutech International AB, Centre Hospitalier St Anne | Cryptogenic Ischemic Stroke, Patent Foramen Ovale | 07/31 | 07/31 | | |
| GRILLOT, Nicolas |
| Not yet recruiting | 3 | 1218 | Europe | direct IV injection, combination of Ketamine and Propofol | Nantes University Hospital | Rapid Sequence Induction | 03/27 | 04/27 | | |
CoC, NCT06194058: Rapid Sequence Intubation and Hemodynamic Disorders in the Operating Room: a Prospective Multicenter Observational Study |
|
|
| Recruiting | N/A | 1150 | Europe | rapid sequence anesthetic induction | Nantes University Hospital, Société Française d'Anesthésie et de Réanimation | Rapid Sequence Intubation | 11/24 | 05/25 | | |
| Figueres, Lucile |
| Terminated | 3 | 667 | Europe, Japan, US, RoW | Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule | Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC | Autosomal Dominant Polycystic Kidney, ADPKD | 08/23 | 08/23 | | |
| Recruiting | N/A | 1343 | Europe, RoW | | Kyowa Kirin Pharmaceutical Development Ltd, Iqvia Pty Ltd | X-Linked Hypophosphatemia | 02/29 | 07/29 | | |
| Recruiting | N/A | 3000 | Europe | No intervention | European Georges Pompidou Hospital, Oscar - Filière Santé Maladies Rares | Hypoparathyroidism | 09/30 | 09/31 | | |
| BREBION, Nicolas |
| Completed | 3 | 1766 | Europe, Canada | Apixaban 5 MG, Apixaban 2.5 MG | Assistance Publique - Hôpitaux de Paris, Bristol-Myers Squibb | Cancer-associated Thrombosis | 09/24 | 10/24 | | |
PRONOSPECT, NCT06372730: Residual Pulmonary Vascular Obstruction Index Computed with Ventilation/perfusion SPECT/CT Imaging to Predict the Risk of Venous Thromboembolism Recurrence in Patients with Pulmonary Embolism |
|
|
| Recruiting | N/A | 665 | Europe | Ventilation/Perfusion Single Photon Emission Computed Tomography (V/Q SPECT/CT) | University Hospital, Brest | Pulmonary Embolism, Venous Thromboembolism | 12/28 | 03/29 | | |
| RAT, Cedric |
IMPACT GP, NCT04689178: Cervical Cancer Screening Uptake: A Randomised Controlled Trial Assessing the Effect of Sending Invitation Letters to Nonadherent Women |
|
|
| Active, not recruiting | N/A | 195000 | Europe | Invitation letter + GP reminder, Invitation letter | Nantes University Hospital | Cervical Cancer | 07/21 | 12/23 | | |
| RAT, Cédric |
SCOPE HPE, NCT06420128: Interprofessional Collaborative Practice in Primary Care: Potentially Avoidable Hospitalization |
|
|
| Not yet recruiting | N/A | 500000 | Europe | Primary care team | Nantes University Hospital | Hospitalization, Aged, Primary Health Care | 12/24 | 12/24 | | |
DEDICACES2, NCT05607849: Breast Cancer Screening Uptake: a Randomized Controlled Trial Assessing the Effect of a Decisional Aid |
|
|
| Not yet recruiting | N/A | 20000 | NA | The decidons ensemble (let's decide together) leaflet and the discutons-mammo.fr (let's talk about breast cancer screening) online tool. | Nantes University Hospital, National Cancer Institute, France, Nantes University hospital, Research Department | Breast Cancer | 06/25 | 09/25 | | |
| Recruiting | N/A | 350 | Europe | Active luminette, Placebo luminette | University Hospital, Strasbourg, France | Insomnia Chronic, Sleep Disorder, Circadian Rhythm Disorders | 02/25 | 02/25 | | |
| FOURNIER, Jean-Pascal |
DeprescrIPPDAM, NCT04513834: Efficacy of a Multi-faceted Intervention Combining an Educational Outreach Visit to General Practitioners and Patient Education Material to Deprescribe Proton Pump Inhibitors (PPI): a Population-based, Pragmatic, Cluster-randomized Controlled Trial |
|
|
| Completed | N/A | 25000 | Europe | GP will receive the educational outreach visit by a DAM (healthcare representative)., Patient education material on PPI deprescribing will be sent to the patients | Nantes University Hospital | Proton Pump Inhibitors, Deprescription | 09/23 | 12/23 | | |
ABC-MG, NCT06067386: Selective Reporting for Antibiotic Susceptibility Testing and GPs' Prescribing of Broad-spectrum Antibiotics in Women With E. Coli UTIs |
|
|
| Recruiting | N/A | 3000 | Europe | Dissemination of a selective reporting for antibiotic susceptibility testing, Standard antibiotic susceptibility testing report | Nantes University Hospital | Urinary Tract Infections | 11/24 | 11/24 | | |
